2022 Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP Group Chronic Malignancies Working Party (CMWP) 1st listed author Francesco Onida Journal Bone Marrow Transplant.
2022 Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Edouard Forcade Journal Bone Marrow Transplant.
2022 Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 Group Chronic Malignancies Working Party (CMWP) 1st listed author Dawn Swan Journal Br J Haematol.
2022 Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Joanna Drozd-Sokołowska Journal Bone Marrow Transplant.
2022 Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT Group Chronic Malignancies Working Party (CMWP) 1st listed author Laure Vincent Journal Bone Marrow Transplant.
2022 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Ali Bazarbachi Journal Clin Cancer Res.
2022 Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Cancer.
2022 Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Transplant Cell Ther.
2022 Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal Bone Marrow Transplant.
2022 Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Cancer Med.
2022 Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) Other society 1st listed author Annalisa Ruggeri Journal Transplant Cell Ther.
2022 Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Clin Cancer Res.